Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02465060
Title Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

multiple myeloma

Advanced Solid Tumor

lymphoma

Therapies

Erdafitinib

Trametinib

Crizotinib

Sapanisertib

AZD4547

Dasatinib

Osimertinib

Palbociclib

Capivasertib

Larotrectinib

Ulixertinib

Nivolumab + Relatlimab

Copanlisib

Sunitinib

Nivolumab

Pertuzumab + Trastuzumab

Ipatasertib

Dabrafenib + Trametinib

Binimetinib

Adavosertib

Afatinib

Defactinib

GSK2636771

Vismodegib

Ado-trastuzumab emtansine

Taselisib

Age Groups: adult
Covered Countries USA